Endoprosthetic proximal femur replacement

Metastatic versus primary tumors

Benjamin K. Potter, Vincent E. Chow, Sheila A Conway, G. Douglas Letson, H. Thomas Temple

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Few studies have examined the impact of underlying diagnosis on the functional and oncologic outcomes following endoprosthetic proximal femur replacement (PFR). We performed a retrospective review of 61 consecutive cemented bipolar PFR in 59 patients for treatment neoplastic lesions with a minimum follow-up of 24 months. Twenty-two patients had primary bone tumors and 39 had metastatic disease. Average follow-up for the 30 surviving patients was 55.4 months and the mean postoperative survival for the 29 patients who died was 12.2 months. Patients with primary tumors demonstrated significantly better functional outcomes than those with metastatic disease, with mean Musculoskeletal Tumor Society functional scores of 80.2 and 66.8%, respectively (p = 0.0002). Age correlated inversely with functional scores (r = -0.48; p = 0.0002), while femoral resection length did not. Preoperative pathologic fracture did not appear to adversely impact final functional outcomes. The Kaplan-Meier 5-year implant survival estimate was 92.5%, with aseptic loosening as the endpoint. Both functional results and survival are increased for primary tumors versus metastatic disease following PFR. However, PFR results in excellent local disease control, reliable pain relief and good functional results in both groups, with prosthesis survival exceeding that of the patient in many cases.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalSurgical Oncology
Volume18
Issue number4
DOIs
StatePublished - Dec 1 2009

Fingerprint

Femur
Neoplasms
Survival
Prosthesis Failure
Spontaneous Fractures
Thigh
Bone and Bones
Pain

Keywords

  • Endoprosthesis
  • Megaprosthesis
  • Metastasis
  • Proximal femur
  • Sarcoma
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Endoprosthetic proximal femur replacement : Metastatic versus primary tumors. / Potter, Benjamin K.; Chow, Vincent E.; Conway, Sheila A; Letson, G. Douglas; Thomas Temple, H.

In: Surgical Oncology, Vol. 18, No. 4, 01.12.2009, p. 343-349.

Research output: Contribution to journalArticle

Potter, Benjamin K. ; Chow, Vincent E. ; Conway, Sheila A ; Letson, G. Douglas ; Thomas Temple, H. / Endoprosthetic proximal femur replacement : Metastatic versus primary tumors. In: Surgical Oncology. 2009 ; Vol. 18, No. 4. pp. 343-349.
@article{48619a9692124dfbab621de9847d492d,
title = "Endoprosthetic proximal femur replacement: Metastatic versus primary tumors",
abstract = "Few studies have examined the impact of underlying diagnosis on the functional and oncologic outcomes following endoprosthetic proximal femur replacement (PFR). We performed a retrospective review of 61 consecutive cemented bipolar PFR in 59 patients for treatment neoplastic lesions with a minimum follow-up of 24 months. Twenty-two patients had primary bone tumors and 39 had metastatic disease. Average follow-up for the 30 surviving patients was 55.4 months and the mean postoperative survival for the 29 patients who died was 12.2 months. Patients with primary tumors demonstrated significantly better functional outcomes than those with metastatic disease, with mean Musculoskeletal Tumor Society functional scores of 80.2 and 66.8{\%}, respectively (p = 0.0002). Age correlated inversely with functional scores (r = -0.48; p = 0.0002), while femoral resection length did not. Preoperative pathologic fracture did not appear to adversely impact final functional outcomes. The Kaplan-Meier 5-year implant survival estimate was 92.5{\%}, with aseptic loosening as the endpoint. Both functional results and survival are increased for primary tumors versus metastatic disease following PFR. However, PFR results in excellent local disease control, reliable pain relief and good functional results in both groups, with prosthesis survival exceeding that of the patient in many cases.",
keywords = "Endoprosthesis, Megaprosthesis, Metastasis, Proximal femur, Sarcoma, Tumor",
author = "Potter, {Benjamin K.} and Chow, {Vincent E.} and Conway, {Sheila A} and Letson, {G. Douglas} and {Thomas Temple}, H.",
year = "2009",
month = "12",
day = "1",
doi = "10.1016/j.suronc.2008.08.007",
language = "English",
volume = "18",
pages = "343--349",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Endoprosthetic proximal femur replacement

T2 - Metastatic versus primary tumors

AU - Potter, Benjamin K.

AU - Chow, Vincent E.

AU - Conway, Sheila A

AU - Letson, G. Douglas

AU - Thomas Temple, H.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Few studies have examined the impact of underlying diagnosis on the functional and oncologic outcomes following endoprosthetic proximal femur replacement (PFR). We performed a retrospective review of 61 consecutive cemented bipolar PFR in 59 patients for treatment neoplastic lesions with a minimum follow-up of 24 months. Twenty-two patients had primary bone tumors and 39 had metastatic disease. Average follow-up for the 30 surviving patients was 55.4 months and the mean postoperative survival for the 29 patients who died was 12.2 months. Patients with primary tumors demonstrated significantly better functional outcomes than those with metastatic disease, with mean Musculoskeletal Tumor Society functional scores of 80.2 and 66.8%, respectively (p = 0.0002). Age correlated inversely with functional scores (r = -0.48; p = 0.0002), while femoral resection length did not. Preoperative pathologic fracture did not appear to adversely impact final functional outcomes. The Kaplan-Meier 5-year implant survival estimate was 92.5%, with aseptic loosening as the endpoint. Both functional results and survival are increased for primary tumors versus metastatic disease following PFR. However, PFR results in excellent local disease control, reliable pain relief and good functional results in both groups, with prosthesis survival exceeding that of the patient in many cases.

AB - Few studies have examined the impact of underlying diagnosis on the functional and oncologic outcomes following endoprosthetic proximal femur replacement (PFR). We performed a retrospective review of 61 consecutive cemented bipolar PFR in 59 patients for treatment neoplastic lesions with a minimum follow-up of 24 months. Twenty-two patients had primary bone tumors and 39 had metastatic disease. Average follow-up for the 30 surviving patients was 55.4 months and the mean postoperative survival for the 29 patients who died was 12.2 months. Patients with primary tumors demonstrated significantly better functional outcomes than those with metastatic disease, with mean Musculoskeletal Tumor Society functional scores of 80.2 and 66.8%, respectively (p = 0.0002). Age correlated inversely with functional scores (r = -0.48; p = 0.0002), while femoral resection length did not. Preoperative pathologic fracture did not appear to adversely impact final functional outcomes. The Kaplan-Meier 5-year implant survival estimate was 92.5%, with aseptic loosening as the endpoint. Both functional results and survival are increased for primary tumors versus metastatic disease following PFR. However, PFR results in excellent local disease control, reliable pain relief and good functional results in both groups, with prosthesis survival exceeding that of the patient in many cases.

KW - Endoprosthesis

KW - Megaprosthesis

KW - Metastasis

KW - Proximal femur

KW - Sarcoma

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=70350567932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350567932&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2008.08.007

DO - 10.1016/j.suronc.2008.08.007

M3 - Article

VL - 18

SP - 343

EP - 349

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 4

ER -